

## General description

Ifosfamide is a nitrogen mustard alkylating agent used in treatment protocols for bone and soft tissue sarcomas, and testicular and ovarian cancers.

INN	Ifosfamide
ATC codes	L01AA06
Medicine type	Chemical agent
EML status history	<p>First added in 2009 (TRS 958) for Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Added in 2009 (TRS 958) for Rhabdomyosarcoma primary site</p> <p>Added in 2009 (TRS 958) for Osteosarcoma of bone and articular cartilage of unspecified sites</p> <p>Added in 2009 (TRS 958) for Other specified malignant neoplasms of the ovary</p> <p>Added in 2009 (TRS 958) for Germ cell tumour of testis</p> <p>Added in 2009 (TRS 958) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Added in 2021 (TRS 1035) for Burkitt lymphoma including Burkitt leukaemia</p> <p>Added in 2021 (TRS 1035) for Malignant neoplasms of kidney, except renal pelvis</p>
Wikipedia	<a href="#">Ifosfamide</a> 
DrugBank	<a href="#">Ifosfamide</a> 

## Recommendations

Section Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

### Indications

Osteosarcoma of bone and articular cartilage of unspecified sites

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Rhabdomyosarcoma primary site

Ewing sarcoma of bone and articular cartilage of unspecified sites

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

